Glooko has gained a $100 million Series F financing and appointed Mike Alvarez as its new CEO.
 
The financing round was led by Georgian, with investments from Health Catalyst Capital, Canaan and other investors and business partners. The proceeds will support Glooko’s expansion in expert data insights, device integrations, clinical research, and chronic condition support.
 
Glooko believes this funding, coupled with the appointment of Alvarez as CEO, will allow it to accelerate global product expansion of its cutting-edge digital healthcare platform and life sciences work, which empowers people with diabetes to better manage their condition and strengthen the engagement with and care from their healthcare team.
 
Alvarez touts over two decades of leadership experience with multinational companies in medical devices and biotech. He was most recently CEO of Qardio, a company focused on remote patient monitoring and tech solutions for chronic disease management.
 
Before Qardio, Alvarez had leadership roles at Medtronic, St. Jude Medical (acquired by Abbott) and Sanofi.
 
“The healthcare industry is currently navigating significant challenges related to data burden and clinical workflows, particularly for physicians working with patients to manage chronic conditions,” said Alvarez. “By unifying data from multiple devices onto one standardized platform, we can simplify decision-making and empower providers to translate vast amounts of data into meaningful insights. This enables timely interventions and helps create new clinical care pathways that can enhance patient outcomes. I am thrilled to join Glooko at this pivotal moment in its journey. I look forward to continued commercial acceleration as we leverage real-world data to transform chronic condition management and improve enrollment and management in clinical trials through diverse and inclusive populations.”